Phase I first-in-human study of TAK-285, a novel investigational dual HER2/EGFR inhibitor, in cancer patients

por Doi, T, Takiuchi, H, Ohtsu, A, Fuse, N, Goto, M, Yoshida, M, Dote, N, Kuze, Y, Jinno, F, Fujimoto, M, Takubo, T, Nakayama, N, Tsutsumi, R
Publicado 2012